欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

您的位置 : 首页  /  MAPK/ERK Pathway  /  p38 MAPK  /  N-(5-(tert-Butyl)-2-methoxy-3-(methylsulfonamido)phenyl)-2-(4-(2-morpholinoethoxy)naphthalen-1-yl)-2-oxoacetamide hydrochloride

CAS No.: 1252679-52-9

N-(5-(tert-Butyl)-2-methoxy-3-(methylsulfonamido)phenyl)-2-(4-(2-morpholinoethoxy)naphthalen-1-yl)-2-oxoacetamide hydrochloride Catalog No. CSN22233

ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1).

规格 价格 促销价格 库存 数量
纯度 & 质量文件 批次:

靶点选择性

生物活性

  • 描述
  • 临床研究
  • NCT号适应症或疾病临床期招募状态预计完成时间地点
    NCT01165359Hepatitis CPhase 1Completed-United States, Alabama ... more >> Alabama Therapeutics CRS Birmingham, Alabama, United States, 35294-2050 United States, California UCLA CARE Center CRS Los Angeles, California, United States, 90035 Ucsd, Avrc Crs San Diego, California, United States, 92103 Ucsf Aids Crs San Francisco, California, United States, 94110 United States, Maryland Johns Hopkins Adult AIDS CRS Baltimore, Maryland, United States United States, New York Univ. of Rochester ACTG CRS Rochester, New York, United States, 14642 United States, North Carolina Duke Univ. Med. Ctr. Adult CRS Durham, North Carolina, United States, 27710 United States, Ohio Univ. of Cincinnati CRS Cincinnati, Ohio, United States, 45267-0405 United States, Pennsylvania Hosp. of the Univ. of Pennsylvania CRS Philadelphia, Pennsylvania, United States, 19104 Puerto Rico Puerto Rico-AIDS CRS San Juan, Puerto Rico, 00935 Collapse <<
    NCT01560468Hepatitis C InfectionPhase 1Terminated(Financial Reasons)-United States, New York ... more >> Mount Sinai School of Medicine New York, New York, United States, 10029 Collapse <<
    NCT01292824Hepatitis C E... more >>vidence of Liver Transplantation Collapse <<Phase 1Completed-United Kingdom ... more >> University Hospital Birmingham Birmingham, West Midlands, United Kingdom, B15 2TH Collapse <<

实验方案

技术信息

CAS号 1252679-52-9 储存条件
分子式 C30H38ClN3O7S 运输 蓝冰
分子量 620.16 别名

大规格询价

号为必填项

姓名: 邮箱: 手机号:
留言:
   提交
联系
我们